SIGA Technologies stock faces longer US wait as Edison trims valuation
Published on 11/13/2026 at 00:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSContract timing weighs on outlook
- Edison expects the next US TPOXX procurement process to extend into 2027.
- A Canadian defence contract offers up to 15 million US dollars through March 2031, with deliveries starting in 2027.
- SIGA now targets 2028 for its supplemental filing covering post-exposure prophylaxis.
SIGA Technologies stock is facing a longer wait for a new US government TPOXX contract after Edison Investment Research said on Thursday, November 12, that the procurement process is likely to extend into 2027. In its latest analysis, Edison kept its expectation of a future US award but highlighted greater timing risk for deliveries and revenue.
The report followed SIGA's third-quarter update for the period ended September 30. Edison said quarterly revenue was 1.3 million US dollars, with no TPOXX product deliveries during the quarter. The company had completed its final delivery under the previous US BARDA 19C contract in the second quarter.
US procurement remains the key swing factor
Edison said the US stockpile requirement remains intact, but the timing of a successor contract has become less certain. Its base case still assumes oral TPOXX deliveries to the US Strategic National Stockpile in 2027, although a later request for proposals would narrow the window for contract award, manufacturing and delivery.
SIGA's international business provides a partial offset. A contract from Canada's Department of National Defence covers up to 15 million US dollars of oral TPOXX purchases through March 31, 2031. About 9 million US dollars represents firm commitments over the first three years, while a further 6 million US dollars depends on options. Deliveries are expected to begin in 2027.
Regulatory timetable moves further out
Edison also said additional validation and laboratory work requested by the US Food and Drug Administration has pushed SIGA's planned supplemental New Drug Application for post-exposure prophylaxis to 2028, from the first half of 2027. Pediatric Phase I results remain targeted for the end of 2026.
The analyst said SIGA ended the third quarter with 116.4 million US dollars in cash and no debt, giving the company time to pursue a new US contract without near-term financing pressure. At the same time, the report noted that a prolonged procurement gap would reduce that flexibility because government orders remain the main driver of revenue and earnings.
SIGA operates in medical countermeasures
SIGA Technologies is a New York-based commercial-stage health security company focused on TPOXX, an antiviral treatment for smallpox and other orthopoxviruses. Its strategy centers on US government partnerships, regulatory expansion, international access and complementary therapeutic areas, according to the company's investor relations page. In the medical-countermeasures market, SIGA is more narrowly focused on an antiviral franchise than Emergent BioSolutions and Bavarian Nordic, which also supply government preparedness products including vaccines and other countermeasures.
SIGA Technologies at a glance
- Company: SIGA Technologies, Inc.
- ISIN: US8269171067
- Ticker: SIGA
- Primary exchange: Nasdaq
- Business: Smallpox and orthopoxvirus medical countermeasures
- Cash and equivalents: 116.4 million US dollars as of September 30, 2026
- Debt: None as of September 30, 2026
US medical-countermeasure companies remain sensitive to government procurement timing. Current S&P 500 market reports provide the broader US market context.
